Your Retinal Risk version1
Research type
Research Study
Full title
Exploring the acceptability and usefulness of a retinal risk screening application to support self-management planning and clinical decision-making.
IRAS ID
286655
Contact name
Roxanne Crosby-Nwaobi
Contact email
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Diabetic retinopathy (DR) is the leading cause of sight loss in people aged 20-69 years. Diminished visual function related to DR, is associated with psychological morbidity and has negative socioeconomic consequences costs for individuals, their families and wider society. National clinical guidelines recommend that patients are given individual feedback on their eye results alongside enhanced metabolic management to reduce risks disease progression. Previous work conducted in patients with mild-moderate diabetic maculopathy, suggest that feedback is often not presented in a manner that is easily accessible and/or understood by the patient. Therefore, the patient is left ill-equipped to manage their condition, as they lack the basic understanding of the disease process and the consequences of poor management.
The RetinaRisk® digital application produces an individualised risk assessment for the development of sight-threatening DR within the next 12 months using a red-amber-green visualisation scale. In this study, we will explore the views of patients and professionals on the acceptability and utility of the RetinaRisk® application for sight-threatening diabetic eye disease to enhance the understanding of their eye condition; and clinical decision-making and activation, including risk sharing and behaviour change.
Research suggests that an understanding of personalised clinical information enables patients to fully participate in the management decisions and care-planning of their condition. The RetinaRisk® application may prove acceptable to patients and clinicians and be amendable to be incorporated into the patient’s consultation.
Following this project, a randomised control trial will be conducted to evaluate the effect of RetinaRisk® on the patient’s eye and metabolic outcomes, knowledge of their condition and any resulting behaviour change.
REC name
Wales REC 4
REC reference
21/WA/0319
Date of REC Opinion
19 Oct 2021
REC opinion
Favourable Opinion